• 中文核心期刊要目总览
  • 中国科技核心期刊
  • 中国科学引文数据库(CSCD)
  • 中国科技论文与引文数据库(CSTPCD)
  • 中国学术期刊文摘数据库(CSAD)
  • 中国学术期刊(网络版)(CNKI)
  • 中文科技期刊数据库
  • 万方数据知识服务平台
  • 中国超星期刊域出版平台
  • 国家科技学术期刊开放平台
  • 荷兰文摘与引文数据库(SCOPUS)
  • 日本科学技术振兴机构数据库(JST)
XU Chang-Long, WANG Jin-Xin, LI Hui-Liang. Two new cyclic bisbibenzyl derivatives from Hebertus dicranus[J]. 中国天然药物, 2016, 14(6): 457-461.
引用本文: XU Chang-Long, WANG Jin-Xin, LI Hui-Liang. Two new cyclic bisbibenzyl derivatives from Hebertus dicranus[J]. 中国天然药物, 2016, 14(6): 457-461.
XU Chang-Long, WANG Jin-Xin, LI Hui-Liang. Two new cyclic bisbibenzyl derivatives from Hebertus dicranus[J]. Chinese Journal of Natural Medicines, 2016, 14(6): 457-461.
Citation: XU Chang-Long, WANG Jin-Xin, LI Hui-Liang. Two new cyclic bisbibenzyl derivatives from Hebertus dicranus[J]. Chinese Journal of Natural Medicines, 2016, 14(6): 457-461.

Two new cyclic bisbibenzyl derivatives from Hebertus dicranus

Two new cyclic bisbibenzyl derivatives from Hebertus dicranus

  • 摘要: In the present study, two new cyclic bisbibenzyls (1, 2) co-occuring with a known compound, isoplagiochins C (3) were isolated from Hebertus dicranus. The structures were determined mainly by extensive 1D and 2D NMR experiments, and the absolute configurations of 1 and 2 were established by the circular dichroism spectrum. Furthermore, all these three rare compounds were tested in vitro for inhibitory activity against the growth of human cancer cell lines (A549, HCT116, MDA-MB-231, and BEL7404) by the MTT assay, and compound 2 exhibited moderately inhibitory activity with IC50 values ranging from 13.89 to 31.62 molL-1. In conclusion, our results provided a basis for future development and modification of these compounds for cancer therapy.

     

    Abstract: In the present study, two new cyclic bisbibenzyls (1, 2) co-occuring with a known compound, isoplagiochins C (3) were isolated from Hebertus dicranus. The structures were determined mainly by extensive 1D and 2D NMR experiments, and the absolute configurations of 1 and 2 were established by the circular dichroism spectrum. Furthermore, all these three rare compounds were tested in vitro for inhibitory activity against the growth of human cancer cell lines (A549, HCT116, MDA-MB-231, and BEL7404) by the MTT assay, and compound 2 exhibited moderately inhibitory activity with IC50 values ranging from 13.89 to 31.62 molL-1. In conclusion, our results provided a basis for future development and modification of these compounds for cancer therapy.

     

/

返回文章
返回